In This Article:
BioNTech (NASDAQ:BNTX) First Quarter 2025 Results
Key Financial Results
-
Revenue: €182.8m (down 2.6% from 1Q 2024).
-
Net loss: €415.8m (loss widened by 32% from 1Q 2024).
-
€1.73 loss per share (further deteriorated from €1.31 loss in 1Q 2024).
We check all companies for important risks. See what we found for BioNTech in our free report.
All figures shown in the chart above are for the trailing 12 month (TTM) period
BioNTech Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 24%.
Looking ahead, revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 2.8% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of BioNTech's balance sheet and an in-depth analysis of the company's financial position.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.